Prognostic markers for systemic sclerosis

Joint Bone Spine

Volumn 73, Issue 5, 2006, Pages 490-494

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Autoantibodies; Prognosis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIOLIPIN ANTIBODY; CD40 LIGAND; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; ENZYME ANTIBODY; HEMOGLOBIN; HOMOCYSTEINE; PEPTIDE; PROTEIN; PROTEIN KL6; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY TITER; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; FIBROSING ALVEOLITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG DISEASE; MORTALITY; OXIDATIVE STRESS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; SHORT SURVEY; SKIN DISEASE; SURVIVAL TIME; SYSTEMIC SCLEROSIS; BLOOD; IMMUNOLOGY; REVIEW; RISK FACTOR;

AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 33750594338     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.01.022     Document Type: Short Survey

References (35)

1. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Cazon M., and Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic cohort. Rheumatol. 43 (2004) 1129-1137
2. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillepsie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48 (2003) 2246-2255
3. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23 (1980) 581-590
4. LeRoy E.C., and Medsger Jr. T.A. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28 (2001) 1573-1576
5. Steen V.D. Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum. 35 (2005) 35-42
6. Scussel-Lonzetti L., Joyal F., Raynaud J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 81 (2002) 154-167
7. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 81 (2002) 139-153
8. Altman R.D., Medsger Jr. T.A., Bloch D.A., and Michel B.A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 34 (1991) 403-413
9. Bryan C., Howard Y., Brennan P., Black C., and Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br. J. Rheumatol. 35 (1996) 112-176
10. Reveille J.D., Solomon D.H., and American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 49 (2003) 399-412
11. Hachulla E., and Dubucquoi S. Intérêt des anticorps antinucléaires pour le diagnostic, la classification et le pronostic de la sclérodermie systémique. Rev. Med. 25 (2004) 442-447
12. Raijmakers R., Renz M., Wiemann C., Egberts W.V., Seelig H.P., van Venrooij W.J., et al. PM-Scl-75 is the main autoantigen in patients with the polymyosites/scleroderma overlap syndrome. Arthritis Rheum. 50 (2004) 565-569
13. Kuwana M., Kaburaki J., Okano Y., Tojo T., and Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 37 (1994) 75-83
14. Reveille J.D., Fischback M., Mcnearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Sem. Arthritis Rheum. 30 (2001) 332-346
15. Kuwana M., Okano Y., Kaburki J., Tojo T., and Medsger Jr. T.A. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 37 (1994) 902-906
16. Davis P., Stein M., Ley H., and Johnston C. Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann. Rheum. Dis. 48 (1989) 73-76
17. Tormey V.J., Bunn C.C., Denton C.P., and Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheum 40 (2001) 1157-1162
18. Meyer O.C., Fertig N., Lucas M., Somogyi N., and Medsger T.A. Antinuclear antibody (ANA) profiles and organ system involvements in 127 French and 247 US adult systemic sclerosis (SSc) patients. Arthritis Rheum 50 Suppl 9 (2004) S632 (abstract 1684)
19. Vesely R., Vargova V., Ravelli A., Massa M., Oleksak E., d'Alterio R., et al. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J. Rheumatol. 31 (2004) 795-800
20. Yanaba K., Hasegawa M., Hamaguchi Y., Fujimoto M., Takehara K., and Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin. Exp. Rheumatol. 21 (2003) 429-436
21. Nagy Z., and Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin. Exp. Rheumatol. 23 (2005) 165-172
22. Caramaschi P., Martinelli N., Biasi D., Carletto A., Faccini G., Volpe A., et al. Homocysteine plasma concentration is related to severity of lung impairment in scleroderma. J. Rheumatol. 30 (2003) 298-304
23. McHugh N.J., Distler O., Giacomelli R., and Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin. Exp. Rheumatol. 21 Suppl. 2 (2003) S32-S38
24. Kodera M., Hasegawa M., Komura K., Yanaba K., Takehara K., and Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis. A sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 52 (2005) 2889-2896
25. Allanore Y., Borderie D., Meune C., Lemaréchal H., Weber S., Ekindjian O.G., et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann. Rheum. Dis. 64 (2005) 481-483
26. Allanore Y., Borderie D., Meune C., Cabanes L., Weber S., Ekindjian O.G., et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum. 48 (2003) 3503-3508
27. Del Papa N., Colombo G., Fracchiolla N., Moronetti L.M., Ingegnoli F., Maglione W., et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum. 50 (2004) 1296-1304
28. Launay D., Hachulla E., Hatron P.Y., Michon-Pasturel U., Hebbar M., Queyrel V., et al. Dépistage de l'hypertension artérielle pulmonaire au cours de la sclérodermie systémique: étude d'une cohorte de 67 patients. Rev. Med. Interne 21 (2001) 819-829
29. Vancheeswaran R., Magoulas T., Efrat G., Wheeler-Jones C., Olsen I., Penny R., et al. Circulating endothelin-1 levels in systemic sclerosis subsets. A marker of fibrosis or vascular dysfunction?. J. Rheumatol. 21 (1994) 1838-1844
30. Allanore Y., Borderie D., Lemaréchal H., Ekindjian O.G., and Kahan A. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res. Ther. 6 (2004) R309-RR14
31. Del Rosso A., Distler O., Milia A.F., Emanueli C., Ibba-Manneschi L., Guiducci S., et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann. Rheum. Dis. 64 (2005) 382-387
32. Riccieri V., Rinaldi T., Spadaro A., Scrivo R., Ceccarelli F., Di Franco M., et al. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin. Rheumatol. 22 (2003) 102-106
33. Blann A.D., Illingworth K.J., and Jayson M.I.V. Raised concentrations of von Willebrand factor antigen in systemic sclerosis. Ann. Rheum. Dis. 50 (1991) 337-338
34. Gruschwitz M.S., Hornstein O.P., and von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 38 (1995) 184-189
35. Herrick A.L., Illingworth K., Blann A., Hay C.R.M., Hollis S., and Jayson M.I.V. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann. Rheum. Dis. 55 (1996) 122-127